Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)

Completed

• Conditions: Hypertension

• Registration Number: NCT01368185
• Lead Sponsor: Organon and Co

Brief Summary

This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg \[Hyzaar(R)\]) treatment for a period of at least three months on serum uric acid levels.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-11
• Primary Completion: 2010-08
• Study Completion: 2010-08
• Study First Submitted: 2011-06-06
• Study First Submitted QC: 2011-06-06
• Study First Posted: 2011-06-07
• Results First Submitted: 2011-08-02
• Results First Submitted QC: 2011-08-02
• Results First Posted: 2011-09-01
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-07
• Last Update Posted: 2022-02-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1705

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum Uric Acid (SUA) Level	Baseline and Month 3	SUA at baseline and Month 3.

Secondary Outcome Measures

Name	Time	Method
Diastolic Blood Pressure (DBP)	Baseline and Month 3	DBP at baseline and month 3.
The Percentage of Patients With Hyperuricemia	Baseline and Month 3	Hyperuricemia was defined as SUA \>6.6mg/dL in females and \>7.7mg/dL in males.
Systolic Blood Pressure (SBP)	Baseline and Month 3	SBP at baseline and month 3.